DISCOVER

Vascepa

EXPERIENCED

in lipid science

INVESTOR

relations

Vascepa

LIPID SCIENCE

investor relations

welcome


therapeutics to improve cardiovascular health

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. For more information about Vascepa visit www.vascepa.com.

recent news


21 Mar 2017

Amarin Corporation CEO, John Thero, to Chair the American Heart Association's Heart & Stroke Ball in New York City MORE

16 Mar 2017

Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study MORE

Stock Information

Symbol:
AMRN (NASDAQ)
Quote:
3.19
Change:
+0.05
Date:
Fri, 24 Mar 2017 16:00
(20 minute delayed share price)
Investor
Relations
Executive
Team
Career
Opportunities
Contact
Amarin

Amarin
Corporation

therapeutics to improve
cardiovascular health.

Join Our Mailing List

You may automatically receive Amarin Corporation plc financial information by email.


Click To Subscribe